Press release
Cytomegalovirus Infection Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
Cytomegalovirus Infection Clinical Trials
As per DelveInsight's assessment, globally, Cytomegalovirus Infection pipeline constitutes 15+ key companies continuously working towards developing 20+ Cytomegalovirus Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Cytomegalovirus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Cytomegalovirus Infection Pipeline Report:
• Cytomegalovirus Infection Companies across the globe are diligently working toward developing novel Cytomegalovirus Infection treatment therapies with a considerable amount of success over the years.
• Cytomegalovirus Infection companies working in the treatment market are antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others, are developing therapies for the Cytomegalovirus Infection treatment
• Emerging Cytomegalovirus Infection therapies in the different phases of clinical trials are- Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others are expected to have a significant impact on the Cytomegalovirus Infection market in the coming years.
• In February 2025, Takeda announced results of an Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Maribavir in Chinese Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Cidofovir or Foscarnet
• In December 2024, ModernaTX, Inc announced results of a Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
• In June 2024, SymBio Pharmaceuticals announced results of a Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection
• In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrates superior efficacy in stimulating the immune system to combat cytomegalovirus infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.
• In June 2023, The FDA sanctioned letermovir for shielding adult kidney transplant recipients at elevated risk (where the donor has CMV antibodies and the recipient does not). Letermovir, a novel non-nucleoside medication, is the first of its kind designed to impede viral replication by specifically targeting the viral terminase complex.
Cytomegalovirus Infection Overview
Cytomegalovirus (CMV) infection is a common viral infection caused by the Cytomegalovirus, a member of the herpesvirus family. It is typically asymptomatic in healthy individuals but can cause severe illness in newborns, immunocompromised patients, and organ transplant recipients. CMV spreads through bodily fluids, including saliva, urine, blood, breast milk, and sexual contact.
In healthy individuals, CMV infection often presents with mild flu-like symptoms, such as fever, fatigue, sore throat, and swollen glands. However, congenital CMV, which occurs when the virus is transmitted from mother to fetus during pregnancy, can lead to serious complications, including hearing loss, developmental delays, and vision problems. In immunocompromised individuals, such as those with HIV/AIDS or transplant recipients, CMV can cause severe complications, including pneumonia, retinitis, and gastrointestinal disease.
Cytomegalovirus (CMV) infection Diagnosis is typically confirmed through blood tests, polymerase chain reaction (PCR) testing, or detecting CMV-specific antibodies. Antiviral medications, such as ganciclovir and valganciclovir, are used to treat severe infections, particularly in high-risk patients.
Cytomegalovirus (CMV) infection Prevention strategies include good hygiene practices, safe blood transfusions, and antiviral prophylaxis for immunocompromised individuals. Ongoing research aims to develop a CMV vaccine to reduce the burden of congenital and severe infections.
Get a Free Sample PDF Report to know more about Cytomegalovirus Infection Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Cytomegalovirus Infection Drugs Under Different Phases of Clinical Development Include:
• Research programme: antiviral therapeutics TSRL
• SYN002: Synklino
• Posoleucel: AlloVir
• mRNA-1647: Moderna
• CMV TCR T cell therapy: China Immunotech
• NPC-21: Nobelpharma
• HB-101: Hookipa Biotech GmbH
• Cytomegalovirus immune globulin: Biotest
• Posoleucel: AlloVir
• VBI-1501A: VBI Vaccines
• LTV 20: Lion TCR
• Maribavir: Shire
• V160: Merck Sharp & Dohme
• Maribavir: Takeda
• Valganciclovir: CSL Behring
• Brincidofovir: Chimerix
• Everolimus: Novartis
• HB-101 vaccine: Hookipa Biotech GmbH
Cytomegalovirus Infection Route of Administration
Cytomegalovirus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal
Cytomegalovirus Infection Molecule Type
Cytomegalovirus Infection Products have been categorized under various Molecule types, such as
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride
Cytomegalovirus Infection Pipeline Therapeutics Assessment
• Cytomegalovirus Infection Assessment by Product Type
• Cytomegalovirus Infection By Stage and Product Type
• Cytomegalovirus Infection Assessment by Route of Administration
• Cytomegalovirus Infection By Stage and Route of Administration
• Cytomegalovirus Infection Assessment by Molecule Type
• Cytomegalovirus Infection by Stage and Molecule Type
DelveInsight's Cytomegalovirus Infection Pipeline Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Cytomegalovirus Infection product details are provided in the report. Download the Cytomegalovirus Infection pipeline report to learn more about the emerging Cytomegalovirus Infection therapies - https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Cytomegalovirus Infection Therapeutics Market include:
Key companies developing therapies for Cytomegalovirus Infection are - Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, and others.
Cytomegalovirus Infection Pipeline Analysis:
The Cytomegalovirus Infection pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.
• Cytomegalovirus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cytomegalovirus Infection drugs and therapies - https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Cytomegalovirus Infection Pipeline Market Drivers
• Increasing Prevalence of Cytomegalovirus Infection, increase in Research and developmental Activities are some of the important factors that are fueling the Cytomegalovirus Infection Market.
Cytomegalovirus Infection Pipeline Market Barriers
• However, high costs associated with the treatment, lack of healthcare infrastructures and other factors are creating obstacles in the Cytomegalovirus Infection Market growth.
Scope of Cytomegalovirus Infection Pipeline Drug Insight
• Coverage: Global
• Key Cytomegalovirus Infection Companies: antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others
• Key Cytomegalovirus Infection Therapies: Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others
• Cytomegalovirus Infection Therapeutic Assessment: Cytomegalovirus Infection current marketed and Cytomegalovirus Infection emerging therapies
• Cytomegalovirus Infection Market Dynamics: Cytomegalovirus Infection market drivers and Cytomegalovirus Infection market barriers
Request for Sample PDF Report for Cytomegalovirus Infection Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Cytomegalovirus Infection Report Introduction
2. Cytomegalovirus Infection Executive Summary
3. Cytomegalovirus Infection Overview
4. Cytomegalovirus Infection- Analytical Perspective In-depth Commercial Assessment
5. Cytomegalovirus Infection Pipeline Therapeutics
6. Cytomegalovirus Infection Late Stage Products (Phase II/III)
7. Cytomegalovirus Infection Mid Stage Products (Phase II)
8. Cytomegalovirus Infection Early Stage Products (Phase I)
9. Cytomegalovirus Infection Preclinical Stage Products
10. Cytomegalovirus Infection Therapeutics Assessment
11. Cytomegalovirus Infection Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cytomegalovirus Infection Key Companies
14. Cytomegalovirus Infection Key Products
15. Cytomegalovirus Infection Unmet Needs
16 . Cytomegalovirus Infection Market Drivers and Barriers
17. Cytomegalovirus Infection Future Perspectives and Conclusion
18. Cytomegalovirus Infection Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus Infection Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight here
News-ID: 3899648 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Cytomegalovirus
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Cytomegalovirus Solutions Soar: Cytomegalovirus Treatment Market Targets US$ 326 …
The Cytomegalovirus (CMV) Treatment Market stands at the forefront of addressing a formidable viral adversary that often operates under the radar. Cytomegalovirus, a member of the herpesvirus family, can pose serious threats to individuals with weakened immune systems, such as transplant recipients and those living with HIV. As a result, the development of effective treatments has become a critical endeavor in the realm of infectious diseases.
In 2022, the global cytomegalovirus…
Cytomegalovirus Treatment Market Will Generate Record Revenue by 2029
The global cytomegalovirus treatment market is anticipated to grow at a CAGR of 30.1% during the forecast period (2023-2030). Cytomegalovirus is one of the most common and serious post-transplant infections and can lead to loss of transplanted organ and failure of graft. It has a global estimated incidence rate of 16.0%-56.0% in SOT recipients and 30.0%-70.0% in HSCT recipients.More than 34,000 SOTs and more than 48,000 HSCTs were performed in…
Cytomegalovirus Diagnostics Market Research Insights, Trends Forecast 2022-28
The global cytomegalovirus diagnostics market size was valued at USD 73.6 million in 2021, growing at a CAGR of 6.1% during the forecast period 2022-28. A common herpesvirus called cytomegalovirus can produce a wide range of symptoms, from little to no symptoms to fever and tiredness to severe symptoms affecting the brain, eyes, and other internal organs. Plasma, sperm, saliva, urinalysis, and breast milk can all be used as…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
